Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva Pharmaceutical Industries Stock Up 1.3 %

Shares of TEVA Stock traded up $0.13 during trading on Friday, reaching $10.47. 509,526 shares of the company's stock were exchanged, compared to its average volume of 20,586,338. The company has a quick ratio of 0.74, a current ratio of 1.11 and a debt-to-equity ratio of 2.07. Teva Pharmaceutical Industries has a twelve month low of $6.78 and a twelve month high of $11.34. The firm's fifty day moving average price is $8.49 and its 200-day moving average price is $8.57.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TEVA. The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 2nd. Piper Sandler lowered Teva Pharmaceutical Industries from a "neutral" rating to an "underweight" rating and lowered their target price for the company from $11.00 to $7.00 in a research note on Wednesday, May 4th. UBS Group assumed coverage on Teva Pharmaceutical Industries in a research report on Monday, June 13th. They issued a "neutral" rating and a $10.00 price objective for the company. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday, June 17th. Finally, Bank of America upgraded Teva Pharmaceutical Industries from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $10.00 to $13.00 in a research report on Friday, August 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Hold" and an average target price of $10.67.

Insider Activity

In related news, VP David Matthew Stark sold 58,163 shares of the company's stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $9.04, for a total transaction of $525,793.52. Following the completion of the sale, the vice president now directly owns 2,974 shares in the company, valued at approximately $26,884.96. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.82% of the company's stock.